Who
David P. Schenkein
Director
Company insider
Files Form 4 as: Director, Prime Medicine; Director, Denali Therapeutics; Director, Regeneron Pharmaceuticals; Chief Executive Officer, Agios Pharmaceuticals; Director, bluebird bio; Director, Foundation Medicine.
In numbers
- Trades disclosed
- 358
- Buys
- 2
- Sells
- 68
- Bought
- $350K
- Sold
- $70.8M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 30 Sep 2013
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,408 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,226 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,226 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,408 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —155 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,962 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,962 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —155 at $0.00 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —39,062 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,062 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,000 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 | filing |
| 4 Jun 2025filed 5 Jun 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,111 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,037 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,958 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —166 at $0.00 | filing |
| 11 Nov 2024filed 13 Nov 2024 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —47,165 at $0.00 | filing |
News
Denali Therapeutics (NASDAQ:DNLI) vs. Century Therapeutics (NASDAQ:IPSC) Head-To-Head ContrastDNLI · themarketsdaily.com · 19 Oct 2026Denali Therapeutics (NASDAQ:DNLI) and Absci (NASDAQ:ABSI) Head to Head ComparisonDNLI · tickerreport.com · 11 Oct 2026Agios Pharmaceuticals (NASDAQ:AGIO) Stock Gets Price Target Reduction from Truist FinancialAGIO · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name David P. Schenkein; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.